INS and cancer: According to Bowker and associates in 2006 [55], patients experiencing type 2 diabetes who were subjected to exogenous insulin and sulfonylureas were at considerably higher risk of dying from cancer than those who were administered metformin [RR 0.82; 95% CI (0.61–0.91)].